Corvex (MOVE) Q1 2025 earnings summary

Executive summary

• Focused on developing medical-grade wearable health devices, with the Evie Ring as the initial commercial product launched in November 2023 and FDA-cleared EvieMED Ring for pulse oximetry in November 2024.

• Revenue is generated solely from U.S. sales of the Evie Ring, with ongoing R&D for next-gen wearables targeting glucose and blood pressure monitoring.

• Company continues to incur net losses and expects to require additional capital to fund operations beyond 2025.

Financial highlights

• Revenue for Q1 2025 was $0.2 million, down 76% from $0.9 million in Q1 2024 due to timing of product transfers.

• Net loss for Q1 2025 was $5.2 million, an improvement from $5.7 million in Q1 2024.

• Cash and cash equivalents as of March 31, 2025 were $4.4 million.

• Operating cash outflow for Q1 2025 was $4.3 million.

Outlook and guidance

• Cash on hand is not expected to fund operations beyond 2025; additional financing is required in the second half of 2025.

• Exploring strategic alternatives, including sale of securities or partnerships, and engaged financial and legal advisors.

• Expectation of continued significant expenses and operating losses for several years.